Desmoid Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Desmoid Tumor Market Outlook
Thelansis’s “Desmoid Tumor Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Desmoid Tumor treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Desmoid
Tumor Overview
Desmoid
tumor (DT) is a rare type of monoclonal, fibroblastic proliferation that can
have an unpredictable clinical course. The World Health Organization (WHO)
classifies DT as a “clonal fibroblastic proliferation that arises in the deep
soft tissues and is characterized by infiltrative growth and a tendency toward
local recurrence but an inability to metastasize.” While DT can occur in
multiple areas of the same limb or body part, it typically appears in
abdominal, intra-abdominal, and extra-abdominal locations. About 5-10% of DT
cases occur in individuals with familial adenomatous polyposis (FAP). CTNNB1
mutations and APC mutations are mutually exclusive in DT. Diagnosis depends on
a combination of morphologic and immunohistochemical findings. DT is most often
poorly circumscribed on a surgical specimen, featuring a scar-like, whitish-cut
surface and ranging in size. Microscopically, a DT is composed of a
cytologically bland, at most moderately cellular, infiltrative spindle cell
proliferation set in a variably collagenous stroma. Peripheral infiltration of
skeletal muscle is often seen.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment